Reshaping the HIV treatment and prevention landscape
Shifting the paradigm towards long-acting treatment
Cabenuva: world's 1st and only long-acting regimen for HIV treatment
LA preferred by 9/10 patients vs orals¹
Fear of disclosure
38%
reported taking pills everyday means a
greater chance of revealing their HIV
status to others²
Anxiety with staying adherent
LA injectable treatment market £4-5bn by 2030
gsk
- Integrase inhibitor at core provides unique resistance
and tolerability profile versus competition
-
― Treatment dosing days reduced from 365 to 6
- Five-year head start over competition
-
Patent protection extends through 2031*
said that needing to take treatment
33%
every day causes stress or anxiety²
Daily reminder of HIV
58%
reported that taking pills for HIV every day
is a daily reminder of HIV in their life²
1. In ATLAS and FLAIR studies
2. ViiV Healthcare. 2020. Positive Perspectives Wave 2 Study
*
Cabotegravir is protected by composition of matter patent protections through 2031 in US and EU and assuming patent term extensions granted
76View entire presentation